SCHEMBL2844152

SCHEMBL2844152

COCCN1CN(CCOC)CN(CCOC)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.41
HSD11B1 P28845 1/20 0.35
ALDH1A1 P00352 4/20 0.34
TDP1 Q9NUW8 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
LMNA P02545 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32
ALOX15 P16050 1/20 0.32
CYP2C19 P33261 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CYP2D6 P10635 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
SLC6A3 Q01959 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8585937 0.82 ALDH1A1 (0.36) GBA1ALDH1A1TDP1KDM4EMEN1
SCHEMBL6057032 0.81
SCHEMBL8149011 0.81 HSD11B1 (0.47) GBA1HSD11B1ALDH1A1TDP1KDM4E
SCHEMBL4893194 0.81 HSD11B1 (0.47) GBA1HSD11B1ALDH1A1TDP1KDM4E
SCHEMBL8353448 0.80 GBA1 (0.46) GBA1HSD11B1ALDH1A1KDM4EMEN1
SCHEMBL8584708 0.78 ALDH1A1 (0.38) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL1220049 0.77
SCHEMBL12454 0.77
SCHEMBL2074984 0.77
SCHEMBL9060463 0.76 HSD11B1 (0.38) GBA1HSD11B1ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025030242-A1 HYDROGEN SULFIDE TRAPPING COMPOUNDS, COMPOSITIONS COMPRISING SAME AND USES THEREOF HYDRO-QUéBEC (CA) 2025-02-13 WO disclosed
EP-3283600-B1 METHOD OF REDUCING HYDROGEN SULFIDE LEVELS IN LIQUID OR GASEOUS STREAMS USING COMPOSITIONS COMPRISING TRIAZINES AND ANIONIC SURFACTANTS DOW GLOBAL TECHNOLOGIES LLC (US) 2019-09-25 EP disclosed
US-10155911-B2 Method of reducing hydrogen sulfide levels in gaseous mixtures using triazines DOW GLOBAL TECHNOLOGIES LLC (US) 2018-12-18 US disclosed
US-20180044598-A1 METHOD OF REDUCING HYDROGEN SULFIDE LEVELS IN GASEOUS MIXTURES USING TRIAZINES DOW GLOBAL TECHNOLOGIES LLC 2018-02-15 US disclosed
US-20100273833-A1 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS MERCKLE GMBH (DE) 2010-10-28 US disclosed
EP-1853581-B1 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS MERCKLE GMBH (DE) 2010-06-02 EP disclosed
US-20100069436-A1 IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT Merckle (DE) 2010-03-18 US disclosed
EP-1894925-A1 Imidazole compounds having an antiinflammatory effect MERCKLE GMBH (DE) 2008-03-05 EP disclosed
US-5744024-A SCAVENGING USING MIXTURE OF HEXAHYDRO-1,3,5-TRIAZINE AND QUATERNARY AMMONIUM COMPOUND NALCO/EXXON ENERGY CHEMICALS, L.P. (US) 1998-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10155911-B2 Method of reducing hydrogen sulfide levels in gaseous mixtures using triazines TST, GSS, SCLY GBA1 1763/4885HSD11B1 458/4885ALDH1A1 1207/4885
US-20100069436-A1 IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT MIF, TNF, IL1B GBA1 4303/4885HSD11B1 850/4885ALDH1A1 572/4885
US-20100273833-A1 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS IL2, IL2RA, IL1B GBA1 2783/4885HSD11B1 1421/4885ALDH1A1 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.